Search

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients

Weill Cornell Medicine And Newyork-presbyterian Hospital Join Boehringer Ingelheim To Study The Incidence Of Progressive Interstitial Lung Disease In Covid-19 Patients

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Retinal Diseases

Let’s find CKD

More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

FDA Grants Priority Review for Spesolimab | BI US

Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.

FIBRONEER™ trials for IPF, other progressive fibrosing ILDs

Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program

New consortium EUbOPEN will provide tools to unlock disease biolog

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Fighting Rabies from the Air | Boehringer Ingelheim US

Click here to read more on how Boehringer Ingelheim is fighting diseases from the air, preventing the spread of the disease with our vaccine.

Thinking differently could eradicate some areas of retinal disease

Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

Partnering in CardioMetabolic Diseases

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US

Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Boehringer Ingelheim launches vaccine to protect poultry from three diseases

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients

Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease

Retinal Diseases

Let’s find CKD

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

Top-line Phase II Data for treatment of MASH

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

FDA Grants Priority Review for Spesolimab | BI US

FIBRONEER™ trials for IPF, other progressive fibrosing ILDs

New consortium EUbOPEN will provide tools to unlock disease biolog

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Fighting Rabies from the Air | Boehringer Ingelheim US

Thinking differently could eradicate some areas of retinal disease

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

Partnering in CardioMetabolic Diseases

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Boehringer Ingelheim launches vaccine to protect poultry from three diseases